EDIT
HEALTHCAREEditas Medicine Inc
AI Insight
What's Moving EDIT Today?
No stock-specific AI insight has been generated for EDIT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.66$4.54
$2.80
Fundamentals
Market Cap$440M
P/E Ratio—
EPS$-1.14
Dividend Yield—
Dividend / Share—
ROE-326.1%
Profit Margin-281.6%
Debt / Equity—
Trading
Volume3.8M
Avg Volume (10D)—
Shares Outstanding153.5M
EDIT News
22 articles- Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?Yahoo Finance·Jun 4, 2026
- CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?The Motley Fool·May 31, 2026
- EDIT (NASDAQ) insider notice: 15,000-share resale; 32,957 RSUs vestedStock Titan·May 29, 2026
- Editas Medicine Announces Updated Presentation Time for Upcoming Investor ConferenceYahoo Finance·May 28, 2026
- Editas Medicine Announces Pricing of Up to $319.4 Million Public OfferingYahoo Finance·May 26, 2026
- Editas Medicine Announces Proposed Public OfferingYahoo Finance·May 26, 2026
- Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society CongressYahoo Finance·May 26, 2026
- [Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·May 21, 2026
- Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual MeetingYahoo Finance·May 14, 2026
- Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) EstimatesYahoo Finance·May 11, 2026
- EDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusYahoo Finance·May 6, 2026
- Company News for May 6, 2026Yahoo Finance·May 6, 2026
- Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Editas Medicine Announces First Quarter 2026 Results and Business UpdatesYahoo Finance·May 5, 2026
- Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific ConferencesYahoo Finance·Apr 27, 2026
- Neutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerGlobeNewswire Inc.·Apr 15, 2026
- Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?Yahoo Finance·Apr 15, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·Apr 13, 2026
- Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?Yahoo Finance·Apr 8, 2026
- Why Investors Need to Take Advantage of These 2 Medical Stocks NowYahoo Finance·Apr 7, 2026
- Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 InterferenceYahoo Finance·Mar 27, 2026
- Is Editas Medicine Going to $0?Motley Fool·Mar 17, 2026
All 22 articles loaded
Price Data
Open$2.76
Previous Close$2.76
Day High$2.97
Day Low$2.76
52 Week High$4.54
52 Week Low$1.66
52-Week Range
$1.66$4.54
$2.80
Fundamentals
Market Cap$440M
P/E Ratio—
EPS$-1.14
Dividend Yield—
Dividend / Share—
ROE-326.1%
Profit Margin-281.6%
Debt / Equity—
Trading
Volume3.8M
Avg Volume (10D)—
Shares Outstanding153.5M
About Editas Medicine Inc
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—